Most importantly, an increased FGF-2 level was found in plasma samples of patients affected by diverse malignancies, such as leukemia and lung and breast cancers, especially when metastases are present and therefore suggested increased FGF-2 levels in serum as a complement predictor of poor prognosis. This evidence concerns the gene FGF2 and leukemia.